Adjuvant radiation therapy is administered post-prostatectomy based on pathological findings, while salvage therapy is for rising PSA levels.
2
Adjuvant radiation significantly reduces the risk of PSA recurrence by over 50%, with biochemical recurrence-free survival rates of 65% versus 36% at 10 years.
3
Fewer than 10% of high-risk prostate cancer patients receive adjuvant radiation, potentially due to practice patterns and concerns about overtreatment.
4
Recent trials, including the RADICALS and RAVES trials, compare adjuvant versus early salvage radiation, showing similar biochemical progression outcomes.
5
Meta-analysis of recent trials indicates minimal differences in PSA-driven event-free survival between adjuvant and early salvage radiation therapies.
